Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Commercial Companies

'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy

Executive Summary

Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.

You may also be interested in...



Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him

O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.

CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

Table

View full table

Related Content

Pink Sheet
In Vivo
Scrip
In Vivo
In Vivo
Scrip

Topics

Related Companies

Tags:
Business Strategies Commercial Companies
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC122984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By